|
Vertical Talus
|
|
0.030 |
GeneticVariation
|
BEFREE |
JAK2 V617F was positive in four out of seven patients with PVT and in one CVT patient.
|
21893442 |
2011 |
|
Vertical Talus
|
|
0.030 |
GeneticVariation
|
BEFREE |
Screening for the JAK2 V617F mutation in CVT patients seems to be useful even in the absence of overt MPN and/or in the presence of other risk factors for CVT because of its relatively high prevalence and the risk of thrombosis recurrence.
|
28609766 |
2017 |
|
Vertical Talus
|
|
0.030 |
GeneticVariation
|
BEFREE |
Thrombophilia abnormalities were significantly more prevalent in the MPN-CVT and MPN-VT than in MPN-NoT group (P = 0.015), as well as the JAK2 V617F mutation in patients with essential thrombocythemia (P = 0.059).
|
25042466 |
2014 |
|
Venous Thromboembolism
|
|
0.060 |
GeneticVariation
|
BEFREE |
The somatic mutation of JAK2 V617F and CALR mutations are less frequent causes of VTE, thus routine testing for these mutations is not recommended.
|
26304686 |
2017 |
|
Venous Thromboembolism
|
|
0.060 |
GeneticVariation
|
BEFREE |
Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, compared with noncarriers, and recent evidence of splanchnic and cerebral vein thrombosis in carriers of the Janus kinase 2 Val617Phe mutation has been reported.
|
18600099 |
2008 |
|
Venous Thromboembolism
|
|
0.060 |
GeneticVariation
|
BEFREE |
The JAK2(V617F)mutation is recurrent in polycythemia vera and essential thrombocythemia, which are myeloproliferative neoplasms frequently associated with arterial and venous thromboembolism.
|
20551270 |
2010 |
|
Venous Thromboembolism
|
|
0.060 |
GeneticVariation
|
BEFREE |
The JAK2 (Janus kinase 2) V617F mutation is a well-known point mutation which is involved in the pathogenesis of IBD, and VTE.
|
31069840 |
2019 |
|
Venous Thromboembolism
|
|
0.060 |
GeneticVariation
|
BEFREE |
JAK2 V617F somatic mutation positives versus negatives had higher erythrocyte (P = 2 × 10(-5) ), thrombocyte (P = 2 × 10(-16) ), and leucocyte (P = 4 × 10(-9) ) counts, and had 2·7-/2·5-fold risk of cancer (prevalent/incident), 44-/28-fold risk of haematological cancer, 221-/97-fold risk of myeloproliferative cancer, 2·2-/1·2-fold risk of ischaemic heart disease, and 3·1-/1·0-fold risk of venous thromboembolism.
|
23116358 |
2013 |
|
Venous Thromboembolism
|
|
0.060 |
GeneticVariation
|
BEFREE |
Individuals harboring JAK2 V617F mutation, regardless of MPN type, were at higher risk of VTE (OR=5.15, 95%CI: 1.16-22.90, P=0.024), mainly deep vein thrombosis (DVT).
|
25559461 |
2015 |
|
Vascular Hemostatic Disorders
|
|
0.010 |
GeneticVariation
|
BEFREE |
JAK2(V617F), the main mutation involved in MPN, is considered as a risk factor for thrombosis, although the direct link between the mutation and hemostatic disorders is not strictly established.
|
24951423 |
2014 |
|
Undifferentiated leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
It is hoped that the same will happen in other MPN with specific genetic alterations: polycythemia vera (JAK2 V617F and other JAK2 mutations), essential thrombocythemia (JAK2V617F and MPL515 mutations), primary myelofibrosis (JAK2 V617F and MPL515 mutations), systemic mastocytosis (KITD816V and other KIT mutations) and stem cell leukaemia/lymphoma (ZNF198-FGFR1 and other FGFR1 fusion genes).
|
19175693 |
2009 |
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
|
23558526 |
2013 |
|
Tuberculosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
We present here a 56-year-old woman with PV harboring a JAK2(V617F) mutation that had a diffuse reticulonodular pattern on chest radiography and was initially suspected of having military tuberculosis.
|
21790864 |
2011 |
|
Trigeminal Neuralgia
|
|
0.010 |
GeneticVariation
|
BEFREE |
There was no significant difference in the occurrence of thrombotic events among CARL-mutant, JAK2 V617F-mutant and TN patients.
|
29725364 |
2018 |
|
Toxic Epidermal Necrolysis
|
|
0.010 |
GeneticVariation
|
BEFREE |
26 (39%) of 66 haematological responders and 25 (71%) of 35 molecular responders (with the JAK2 Val617Phe mutation) have maintained some response during follow-up: 49% maintained their best molecular response (nine of ten patients who had a complete response, five of 20 who had a partial response, and three of five who had a minor response).
|
28291640 |
2017 |
|
Thymoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
This activity was coupled with inhibition of phosphorylation of the key JAK2(V617F)-dependent downstream signaling effectors signal transducer and activator of transcription (STAT)3, STAT5, and v-akt murine thymoma viral oncogene homolog (AKT).
|
18482053 |
2008 |
|
Thrombosis of cerebral veins
|
|
0.040 |
GeneticVariation
|
BEFREE |
To assess the incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis with or without overt CMD.
|
17263783 |
2007 |
|
Thrombosis of cerebral veins
|
|
0.040 |
GeneticVariation
|
BEFREE |
Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, compared with noncarriers, and recent evidence of splanchnic and cerebral vein thrombosis in carriers of the Janus kinase 2 Val617Phe mutation has been reported.
|
18600099 |
2008 |
|
Thrombosis of cerebral veins
|
|
0.040 |
GeneticVariation
|
BEFREE |
Patients with cerebral venous thrombosis can carry the JAK2 V617F mutation, irrespective of blood count.
|
22469236 |
2012 |
|
Thrombosis of cerebral veins
|
|
0.040 |
GeneticVariation
|
BEFREE |
Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
|
28609766 |
2017 |
|
Thrombophilia, hereditary
|
|
0.010 |
GeneticVariation
|
BEFREE |
Primary thrombophilia in México VII: the V617F mutation of JAK2 is not a frequent cause of thrombosis.
|
18796251 |
2008 |
|
Thrombophilia
|
|
0.080 |
GeneticVariation
|
BEFREE |
We used the thrombin generation assay to evaluate the hypercoagulable state according to JAK2(V617F) mutational status in essential thrombocythemia (ET) and polycythemia vera (PV) patients.
|
18768782 |
2008 |
|
Thrombophilia
|
|
0.080 |
GeneticVariation
|
BEFREE |
Impact of common thrombophilias and JAK2 V617F on pregnancy outcomes in unselected Italian women.
|
21232003 |
2011 |
|
Thrombophilia
|
|
0.080 |
GeneticVariation
|
BEFREE |
A work-up for JAK2 V617F mutation and thrombophilia was done.
|
23941968 |
2013 |
|
Thrombophilia
|
|
0.080 |
GeneticVariation
|
BEFREE |
Accordingly, it seems that the investigation for the V617F mutation of the JAK2 gene is not mandatory in all Mexican mestizo patients with unexplained thrombophilia and that this genetic study should be reserved for special cases, such as patients with thrombosis in uncommon sites or patients with cell counts suggesting the presence of an underlying MPD.
|
18796251 |
2008 |